

Drug Monograph

Drug Name: **Adhansia XR™ (methylphenidate hydrochloride) capsule**
 Drug Class: **ADHD, Methylphenidate, Long Acting**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Adhansia XR (methylphenidate hydrochloride) extended-release capsules are available in 25mg, 35mg, 45mg, 55mg, 70mg, and 85mg strengths.

Manufacturer: Purdue Pharmaceuticals L.P., Wilson, NC 27893

Indications: Adhansia XR is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Costs: Adhansia XR is supplied in bottles of 30 capsules: \$299.40/30 days.

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Appropriate Indications No PA Required
 Non-Preferred Preferred

Prepared By: Jennifer Anderson PharmD, BCPS
 Date: September 28, 2019